Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is currently priced at $8.78, with a 24-hour trading volume of 388.38K. It has seen a +1.27% increased in the last 24 hours and a -16.62% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $8.73 pivot point. If it approaches the $8.86 resistance level, significant changes may occur.

Zymeworks Inc. Stock (ZYME) Financials Data

Zymeworks Inc. (ZYME) Revenue 2024

ZYME reported a revenue (TTM) of $76.01 million for the quarter ending December 31, 2023, a -81.57% decline year-over-year.

Zymeworks Inc. (ZYME) Net Income 2024

ZYME net income (TTM) was -$118.67 million for the quarter ending December 31, 2023, a -195.44% decrease year-over-year.

Zymeworks Inc. (ZYME) Cash Flow 2024

ZYME recorded a free cash flow (TTM) of -$122.38 million for the quarter ending December 31, 2023, a -193.43% decrease year-over-year.

Zymeworks Inc. (ZYME) Earnings per Share 2024

ZYME earnings per share (TTM) was -$1.73 for the quarter ending December 31, 2023, a -197.74% decline year-over-year.

Zymeworks Inc. Stock (ZYME) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Moore Paul Andrew	Chief Scientific Officer	Jan 08 '24	Sale	11.22	2,339	26,233	7,367
Astle Christopher	SVP & Chief Financial Officer	Jan 08 '24	Sale	11.22	1,431	16,050	6,503
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '24	Option Exercise	0.00	17,166	0	17,166
Galbraith Kenneth	Chair & CEO	Jan 05 '24	Option Exercise	0.00	47,666	0	47,666
Astle Christopher	SVP & Chief Financial Officer	Jan 05 '24	Option Exercise	0.00	10,500	0	12,497
Galbraith Kenneth	Chair & CEO	Jan 05 '24	Sale	10.65	18,198	193,849	29,468
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '24	Sale	10.65	7,460	79,465	9,706
Astle Christopher	SVP & Chief Financial Officer	Jan 05 '24	Sale	10.65	4,563	48,606	7,934
Astle Christopher	SVP & Chief Financial Officer	Dec 11 '23	Option Exercise	0.00	1,550	0	2,883
Astle Christopher	SVP & Chief Financial Officer	Dec 11 '23	Sale	9.13	886	8,089	1,997

Zymeworks Inc. Stock (ZYME) Latest News

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

GlobeNewswire Inc.

Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

GlobeNewswire Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Resumed	Wells Fargo: Overweight	Mar-21-23
Reiterated	H.C. Wainwright: Neutral	Jan-04-23
Upgrade	Jefferies: Hold → Buy	Dec-20-22
Downgrade	H.C. Wainwright: Buy → Neutral	Nov-01-22
Downgrade	SVB Leerink: Outperform → Mkt Perform	Oct-21-22
Resumed	Wells Fargo: Overweight	Oct-04-22
Upgrade	Guggenheim: Neutral → Buy	May-05-22
Initiated	Evercore ISI: Outperform	Mar-15-22
Upgrade	SVB Leerink: Mkt Perform → Outperform	Dec-10-21
Resumed	Guggenheim: Neutral	Nov-17-21
Initiated	Jefferies: Hold	Oct-07-21
Initiated	Credit Suisse: Outperform	Mar-31-21
Downgrade	SVB Leerink: Outperform → Mkt Perform	Feb-25-21
Resumed	H.C. Wainwright: Buy	Feb-08-21
Downgrade	Citigroup: Buy → Neutral	Jan-25-21
Resumed	JP Morgan: Neutral	Sep-29-20
Initiated	SVB Leerink: Outperform	Aug-06-20
Initiated	Wolfe Research: Outperform	Jan-10-20
Initiated	JP Morgan: Neutral	Dec-09-19
Initiated	H.C. Wainwright: Buy	Nov-25-19
Initiated	Guggenheim: Buy	Nov-20-19
Upgrade	Raymond James: Outperform → Strong Buy	Sep-30-19
Initiated	Stifel: Buy	Aug-30-19
Initiated	Deutsche Bank: Buy	Jul-18-19
Upgrade	Barclays: Underweight → Equal Weight	May-11-18
Initiated	Raymond James: Outperform	Mar-19-18